Skip to main content
Andrzej Jakubowiak, MD, Oncology, Chicago, IL, University of Chicago Medical Center

AndrzejJJakubowiakMD

Oncology • Chicago, IL

Hematologic Oncology

Professor, Medicine, University of Chicago Div of the Bio Sci The Pritzker SOM

Request Appointment

Overview of Dr. Jakubowiak

Dr. Andrzej Jakubowiak is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Medical Science Poznan and has been in practice 40 years. He is one of 123 doctors at University of Chicago Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1994 - 1997
  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonResidency, Pathology-Anatomic and Clinical, 1992 - 1992
  • University of Medical Science Poznan
    University of Medical Science PoznanClass of 1977

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2011 - 2026
  • NC State Medical License
    NC State Medical License 2021 - 2022
  • MI State Medical License
    MI State Medical License 2000 - 2013
  • NY State Medical License
    NY State Medical License 1997 - 2000

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
    Andrzej Jakubowiak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...
    Andrzej Jakubowiak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)Clinically Releva...
    Andrzej Jakubowiak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Anal... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

  • Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaDecember 2017
  • Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaDecember 2017
  • Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaDecember 2017

Press Mentions

  • Triple Drug Combo Beats Single Therapy in Multiple Myeloma Maintenance
    Triple Drug Combo Beats Single Therapy in Multiple Myeloma MaintenanceJanuary 25th, 2023
  • Triple-Drug Therapy for Post-Transplant Management of Multiple Myeloma
    Triple-Drug Therapy for Post-Transplant Management of Multiple MyelomaJanuary 13th, 2023
  • Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from Treatment
    Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
  • Join now to see all

Hospital Affiliations

Dr. Andrzej Jakubowiak, Dr. Andrzej Jakubowiak, MD, Dr. A Jakubowiak, Dr. Andrzej J Jakubowiak